Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
Open Access
- 1 April 2021
- journal article
- research article
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 84 (2), 96-104
- https://doi.org/10.4046/trd.2020.0109
Abstract
Background: Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life. This study aimed to assess the efficacy and safety of direct switch from once-daily tiotropium (TIO) 18 mu g to indacaterol/glycopyrronium (IND/GLY) 110/50 mu g once daily in COPD patients in Korea. Methods: This was a randomized, open-label, parallel group, 12-week trial in mild-to-moderate COPD patients who received TIO 18 mu g once daily for >= 12 weeks prior to study initiation. Patients aged >= 40 years, with predicted post-bronchodilator forced expiratory volume in 1 second (FEV1) >= 50%, post-bronchodilator FEV1/forced vital capacity = 10 pack-years were included. Eligible patients were randomized in a 1:1 ratio to either IND/GLY or TIO. The primary objective was to demonstrate superiority of IND/GLY over TIO in pre-dose trough FEV1 at week 12. Secondary endpoints included transition dyspnea index (TDI) focal score, COPD assessment test (CAT) total score, and rescue medication use following the 12-week treatment, and safety assessment. Results: Of the 442 patients screened, 379 were randomized and 347 completed the study. IND/GLY demonstrated superiority in pre-dose trough FEV1 versus TIO at week 12 (least squares mean treatment difference [Delta], 50 mL; p=0.013). Also, numerical improvements were observed with IND/GIY in the TDI focal score (Delta, 0.31), CAT total score (Delta, -0.81), and rescue medication use (Delta, -0.09 puffs/day). Both treatments were well tolerated by patients. Conclusion: A direct switch from TIO to IND/GLY provided improvements in lung function and other patient-reported outcomes with an acceptable safety profile in patients with mild-to-moderate airflow limitation.Funding Information
- Novartis Korea Ltd.
This publication has 16 references indexed in Scilit:
- Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patientsInternational Journal of Chronic Obstructive Pulmonary Disease, 2017
- Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trialRespiratory Research, 2017
- Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trialTrials, 2017
- Recent Trends in the Prevalence of Chronic Obstructive Pulmonary Disease in KoreaTuberculosis and Respiratory Diseases, 2017
- Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax, 2015
- Prevalence of Chronic Obstructive Lung Disease in Korea Using Data from the Fifth Korea National Health and Nutrition Examination SurveyKorean Journal of Family Medicine, 2015
- Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patientsRespiratory Medicine, 2014
- Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE studyEuropean Respiratory Journal, 2013
- Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?Nephron Clinical Practice, 2011
- The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology & Therapeutics, 2010